An orphan drug designation and results from a phase 3 trial investigating bevacizumab-vikg led recent retina/vitreous coverage on Healio/OSN.
Read the best-performing retina/vitreous articles below.
FDA grants orphan drug designation to ADX-2191 for retinitis pigmentosa
The FDA has granted orphan drug designation to ADX-2191 for the treatment of retinitis pigmentosa, according to a press release from Aldeyra Therapeutics. Read more.
Bevacizumab-vikg meets endpoints in phase 3 wet AMD trial
ONS-5010 demonstrated statistically significant results in the treatment of patients with wet age-related